BioPatch, and alternatives like Tegaderm CHG, are an important first step in helping prevent catheter-related bloodstream infections (CBIs). As CBIs rank among the most frequent and potentially lethal nosocomial infections, the need for a device to cut down infections at the insertion site has increased. The growing numbers of infections has driven companies to consider a three-tiered approach: a maximal aseptic barrier at insertion, proper site maintenance, and hub protection. With BioPatch and alternative products catheter sites receive that maximal aseptic barrier to prevent bacteria growth.
Catheter-Related Bloodstream Infections
According to an article by Timsit, J., et al. an estimated 5 million central venous catheters are inserted in patients each year. CBIs, most of which are associated with central venous catheters, account for more than 11% of all health-care associated infections. Additionally, more than 250,000 central-line associated blood stream infections also occur annually, with an estimated mortality rate of 12-25%. For patients within the intensive care unit, the numbers were even higher. Each episode significantly increases the patient’s hospital stay, as well as increasing costs from $4,000 to $56,000 per episode.
CBIs occur when intravascular devices become contaminated on the outer surface during nonaseptic insertion or with improper maintenance of the catheter exit site. CBIs are commonly associated with sepsis, fever, chills and hypotension. Skin flora at the insertion site is the most common source of catheter colonization.
The use of Chlorhexidine gluconate (CHG), a well-known antiseptic agent with broad-spectrum antimicrobial and antifungal activity, to disinfect the skin prior to catheter insertion provides substantial protection against CBIs. However, viable bacteria may still remain on the skin and regrowth occurs over time.
BioPatch is produced by Ethicon, a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line. Ethicon is headquartered in Somerville, New Jersey. It currently conducts business in 52 countries.
BioPatch Protective Disk with CHG provides a maximal aseptic barrier at the catheter exit site, which prevents growth of bacteria that would cause blood-stream infections. BioPatch is a small foam disk that surrounds the catheter site on a patient, and is complete with an antimicrobial dressing.
BioPatch’s antimicrobial action has been shown to extend up to an inch beyond the margin of the disc and to last for up to seven days, according to the Johnson and Johnson manufacturing website. Current published data shows that in both pediatric and adult populations, BioPatch is effective in reducing CRBSIs and site infection in a variety of different catheter types.
A study by Bhende, S., et al. shows that BioPatch is effective...